Uso Compasivo (Spain): how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What Uso Compasivo is
Origin and authorising body. Spain, under Real Decreto 1015/2009 regulating the availability of medicines in special situations. The authorising body for each individual case is the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), with regional autonomous community pharmacy oversight at the dispensing level, acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. Real Decreto 1015/2009 of 19 June 2009 regulates the availability of medicines in special situations in Spain. Article 8 establishes the compassionate-use framework (Uso Compasivo) for medicines in development. Article 13 covers the individual import of foreign medicines for individual patients (Acceso a Medicamentos en Situaciones Especiales). The Spanish framework is integrated with EMA centralised procedures: AEMPS recognises EMA scientific opinions and aligns its compassionate-use decisions accordingly.
Uso Compasivo (Spain) is the Spanish framework for compassionate use of medicines in clinical development. The framework distinguishes between individual-patient compassionate use and cohort-level compassionate use under a defined protocol. AEMPS also operates a separate framework under Article 13 of Real Decreto 1015/2009 for foreign-medicine imports for individual patients where the requested medicine is authorised abroad but not in Spain. The two frameworks together cover most cross-border specialty-medicine scenarios that arise in Spanish clinical practice.
Spain's regional structure means that compassionate-use applications are filed centrally with AEMPS but dispensing operates through hospital pharmacies overseen by the relevant autonomous community (Comunidad Autonoma). Catalonia, Madrid, and Andalusia handle the largest volume of compassionate-use cases. The dispensing hospital pharmacy must be authorised; typically this is a tertiary academic hospital with an existing pharmacy infrastructure for unregistered medicines (Hospital Clinic Barcelona, Hospital Universitario La Paz Madrid, Hospital Vall d'Hebron Barcelona, Hospital Universitario 12 de Octubre Madrid, Hospital Universitario Virgen del Rocio Seville).
This page consolidates Reserve Meds's operational view of the Uso Compasivo (Spain) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Uso Compasivo (Spain)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use Uso Compasivo
Uso Compasivo is used by hospital-affiliated Spanish physicians on behalf of patients with serious or life-threatening conditions for whom no satisfactory authorised alternative exists. Cross-border patients from outside Spain cannot directly use the framework. Spanish patients who require a medicine authorised abroad but not in Spain typically use the Article 13 individual-patient foreign-medicine import framework, which is operationally similar to a Named-Patient route in other jurisdictions.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under Uso Compasivo
Specialty oncology agents (immune checkpoint inhibitors, CAR-T agents, ADCs in pre-Spanish registration), rare-disease biologics, advanced therapy medicinal products, paediatric extensions of adult-approved medicines, and post-approval indications not yet through Spanish registration.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Uso Compasivo (Spain) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the Uso Compasivo (Spain) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Uso Compasivo (Spain) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Uso Compasivo (Spain) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts Uso Compasivo (Spain) dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Indirect (reference precedent only) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Indirect (reference precedent only) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Indirect (reference precedent only) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Indirect (reference precedent only) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Indirect (reference precedent only) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Indirect (reference precedent only) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Indirect (reference precedent only) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Indirect (reference precedent only) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Indirect (reference precedent only) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Indirect (reference precedent only) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept Uso Compasivo (Spain) authorisation as the legal basis for import but does recognise a Uso Compasivo (Spain) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A Uso Compasivo application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- Treating physician's clinical justification.
- Patient clinical history and informed consent.
- Hospital ethics committee approval (Comite Etico de Investigacion Clinica, CEIC).
- Manufacturer letter confirming supply.
- Pharmacy dispensing plan (the dispensing hospital pharmacy must be authorised).
- Quarterly reporting on enrolment and outcomes for cohort cases.
- Article 13 import application where the framework applies.
Typical timeline
AEMPS routine review: 2 to 4 weeks for individual cases, 6 to 12 weeks for new cohort protocols. Article 13 foreign-medicine imports: 2 to 4 weeks. Cross-border patients using parallel home-country frameworks complete in 4 to 8 weeks end-to-end.
Costs and reimbursement
Spanish reimbursement through the Sistema Nacional de Salud may cover compassionate-use medicines depending on indication; this is decided regionally by the relevant autonomous community. Cross-border patients pay the relevant per-country acquisition cost plus logistics, customs, dispensing, and coordinator fees.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Uso Compasivo (Spain) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the Uso Compasivo (Spain) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.